NCT05162469 is a Phase 1 clinical trial of SHR-1909 injection in Advanced Malignant Cancer, sponsored by Shanghai Hengrui Pharmaceutical Co., Ltd..

Who is sponsoring NCT05162469?

NCT05162469 is sponsored by Shanghai Hengrui Pharmaceutical Co., Ltd..

What drugs are being tested in NCT05162469?

Interventions in NCT05162469: SHR-1909 injection.

What condition does NCT05162469 study?

NCT05162469 studies Advanced Malignant Cancer.

Is NCT05162469 still recruiting?

NCT05162469 is currently completed. Last updated 28 July 2025.

Last reviewed 2025-07-28 · How we verify

NCT05162469

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of SHR-A1909 in Subjects With Advanced Malignant Tumors

Completed Phase 1 Last updated 28 July 2025

What this trial tests

Phase 1 trial testing SHR-1909 injection in Advanced Malignant Cancer in 12 participants. Completed in 13 June 2024.

Timeline

23 February 2022

Primary endpoint
28 March 2024

13 June 2024

Quick facts

Lead sponsor	Shanghai Hengrui Pharmaceutical Co., Ltd.
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	12
Start date	23 February 2022
Primary completion	28 March 2024
Estimated completion	13 June 2024
Sites	1 location across China

Drugs / interventions tested

SHR-1909 injection — full drug profile →

Conditions studied

Advanced Malignant Cancer — all drugs for Advanced Malignant Cancer →

Sponsor

Shanghai Hengrui Pharmaceutical Co., Ltd. — full company profile →

Who can join

18 and older, any sex, with Advanced Malignant Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is an, open-label, multi-center, three-part phase I trial to evaluate the safety, pharmacokinetics and immunogenicity of SHR-1909 and preliminary anti-tumor efficacy of SHR-1909 in advanced malignant cancer.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Shanghai Hengrui Pharmaceutical Co., Ltd. trials

Trials by the same sponsor.

NCT06877247 — A Mass Balance Study of [14C] SHR6508 in Chinese Hemodialysis Subjects With Secondary Hyperparathyroidism · Phase 1 · completed
NCT06649292 — SHR-A1904 Compared With Investigator's Choice of Therapy in Claudin18.2 Positive Patitens With Second-line Advanced or M · Phase 3 · recruiting
NCT06654440 — A Trial of SHR-A2102 for Treatment of Advanced Gynecological Malignancy · Phase 2 · recruiting
NCT06639347 — A Trial of SHR-A2102 With Antitumor Therapy in Advanced Urothelial Carcinoma · Phase 1, PHASE2 · recruiting
NCT06605222 — A Trial of SHR-7787 Injection in Patients With Advanced Solid Tumors · Phase 1, PHASE2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05162469 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shanghai Hengrui Pharmaceutical Co., Ltd.
Last refreshed: 28 July 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05162469.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing